284 related articles for article (PubMed ID: 24876732)
1. Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives.
Hohla F; Winder T; Greil R; Rick FG; Block NL; Schally AV
World J Gastroenterol; 2014 May; 20(20):6102-12. PubMed ID: 24876732
[TBL] [Abstract][Full Text] [Related]
2. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
[TBL] [Abstract][Full Text] [Related]
3. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
Pinski J; Halmos G; Szepeshazi K; Schally AV
Cancer; 1993 Dec; 72(11):3263-70. PubMed ID: 8242552
[TBL] [Abstract][Full Text] [Related]
4. Role of Anti-Epidermal Growth Factor Receptor Therapy Compared with Anti-Vascular Endothelial Growth Factor Therapy for Metastatic Colorectal Cancer: an Update Meta-Analysis of Randomized Clinical Trials.
Wang JX; Wu HL; Zhu M; Zhou R
Pathol Oncol Res; 2020 Jan; 26(1):159-166. PubMed ID: 29383654
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy in colorectal cancer: current status and future challenges.
Koutras AK; Starakis I; Kyriakopoulou U; Katsaounis P; Nikolakopoulos A; Kalofonos HP
Curr Med Chem; 2011; 18(11):1599-612. PubMed ID: 21428886
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy for metastatic colorectal cancer.
Price TJ; Tang M; Gibbs P; Haller DG; Peeters M; Arnold D; Segelov E; Roy A; Tebbutt N; Pavlakis N; Karapetis C; Burge M; Shapiro J
Expert Rev Anticancer Ther; 2018 Oct; 18(10):991-1006. PubMed ID: 30019590
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer.
Winder T; Lenz HJ
Gastroenterology; 2010 Jun; 138(6):2163-76. PubMed ID: 20420953
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.
Yano T; Pinski J; Szepeshazi K; Halmos G; Radulovic S; Groot K; Schally AV
Cancer; 1994 Feb; 73(4):1229-38. PubMed ID: 8313327
[TBL] [Abstract][Full Text] [Related]
9. The role of targeted therapy in the treatment of advanced colorectal cancer.
Fakih M
Curr Treat Options Oncol; 2008 Dec; 9(4-6):357-74. PubMed ID: 19238551
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
Mitchell EP
Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
[TBL] [Abstract][Full Text] [Related]
12. Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095.
Szepeshazi K; Schally AV; Halmos G; Groot K; Radulovic S
J Natl Cancer Inst; 1992 Dec; 84(24):1915-22. PubMed ID: 1460673
[TBL] [Abstract][Full Text] [Related]
13. The developing trend of monoclonal antibodies in the treatment of colorectal cancer.
Elfiky AA; Saif MW
Expert Opin Biol Ther; 2007 Jun; 7(6):871-83. PubMed ID: 17555372
[TBL] [Abstract][Full Text] [Related]
14. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer.
Jeong WJ; Cha PH; Choi KY
World J Gastroenterol; 2014 Aug; 20(29):9862-71. PubMed ID: 25110417
[TBL] [Abstract][Full Text] [Related]
15. Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.
Sartore-Bianchi A; Siena S
Handb Exp Pharmacol; 2018; 249():145-159. PubMed ID: 28382467
[TBL] [Abstract][Full Text] [Related]
16. Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs.
Szepesházi K; Halmos G; Schally AV; Arencibia JM; Groot K; Vadillo-Buenfil M; Rodriguez-Martin E
J Cancer Res Clin Oncol; 1999; 125(8-9):444-52. PubMed ID: 10480336
[TBL] [Abstract][Full Text] [Related]
17. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.
Schally AV; Nagy A
Eur J Endocrinol; 1999 Jul; 141(1):1-14. PubMed ID: 10407215
[TBL] [Abstract][Full Text] [Related]
18. Role of targeted agents in metastatic colorectal cancer.
Prenen H; Vecchione L; Van Cutsem E
Target Oncol; 2013 Jun; 8(2):83-96. PubMed ID: 23645285
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor ligands: targets for optimizing treatment of metastatic colorectal cancer.
Foroughi S; Tie J; Gibbs P; Burgess AW
Growth Factors; 2019 Dec; 37(5-6):209-225. PubMed ID: 31878812
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor and metastatic colorectal cancer: insights into target therapies.
de Mello RA; Marques AM; Araújo A
World J Gastroenterol; 2013 Oct; 19(38):6315-8. PubMed ID: 24151349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
